| Overall | Transition to CAF | ||
| CAF | Not CAF | ||
| No of patients | 37 | 8 | 29 |
| Age (years) | 71 (11) | 70 (9) | 71 (12) |
| Gender | |||
| Female | 18 (49%) | 2 (25%) | 16 (55%) |
| Male | 19 (51%) | 6 (75%) | 13 (45%) |
| Body surface area (m2) | 1.6 (0.2) | 1.6 (0.2) | 1.6 (0.2) |
| Antiarrhythmic drugs | 12 (32%) | 3 (37%) | 9 (31%) |
| Cibenzoline | 1 | 0 | 1 |
| Pirmenol | 4 | 2 | 2 |
| Pilsicainide | 7 | 1 | 6 |
| None | 25 | 5 | 20 |
| Angiotensin-converting enzyme inhibitors | 5 | 1 | 4 |
| Diuretics | 3 | 1 | 2 |
Values are mean (SD) or n (%). There were no significant differences between the patients with and without the transition to chronic atrial fibrillation (CAF).